0 152

Cited 2 times in

Intravitreal Bevacizumab for Traumatic Choroidal Rupture

 Min Kim  ;  Jin Hyung Kim  ;  Yuri Seo  ;  Hyoung Jun Koh  ;  Sung Chul Lee 
 OPTOMETRY AND VISION SCIENCE, Vol.92(10) : e363-e367, 2015 
Journal Title
Issue Date
Adolescent ; Angiogenesis Inhibitors/therapeutic use* ; Bevacizumab/therapeutic use* ; Choroid/injuries* ; Eye Injuries/drug therapy* ; Eye Injuries/etiology ; Eye Injuries/physiopathology ; Fluorescein Angiography ; Humans ; Intravitreal Injections ; Male ; Retinal Detachment/drug therapy ; Retinal Detachment/etiology ; Retinal Detachment/physiopathology ; Retinal Hemorrhage/drug therapy ; Retinal Hemorrhage/etiology ; Retinal Hemorrhage/physiopathology ; Rupture ; Tomography, Optical Coherence ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/physiology ; Wounds, Nonpenetrating/drug therapy* ; Wounds, Nonpenetrating/etiology ; Wounds, Nonpenetrating/physiopathology
traumatic choroidal rupture ; intravitreal bevacizumab ; choroidal neovascularization
PURPOSE: To report a case of visual loss associated with traumatic choroidal rupture after blunt ocular trauma that was successfully treated with an early intravitreal bevacizumab injection despite the absence of choroidal neovascularization (CNV). CASE REPORT: A 14-year-old boy presented with visual disturbance in his left eye after sustaining an ocular contusion 4 weeks earlier. The best-corrected visual acuity (BCVA) in the left eye was 20/50. Funduscopic examination revealed macular choroidal rupture accompanied by subretinal hemorrhage. Optical coherence tomography (OCT) showed accumulation of subretinal fluid around a disrupted retinal pigment epithelium/Bruch membrane complex extending into the juxtafoveolar area, but there was no active leakage suggestive of CNV on fluorescein angiography. Intravitreal bevacizumab (1.25 mg) injection was performed to treat persistent serous retinal detachment at macula causing visual loss. There was a reduction of subretinal fluid and concomitant improvement of BCVA to 20/30 within 1 week after intravitreal bevacizumab injection. The BCVA recovered to 20/25 in the left eye after 4 weeks, and only a minimal amount of residual fluid remained according to OCT. Complete resolution of subretinal fluid was observed by OCT at the 6-week follow-up examination, and BCVA improved to 20/20. Good visual acuity (20/20) and stable macula were maintained in the left eye at 1 year of follow-up without recurrence of subretinal fluid accumulation or hemorrhage and CNV. There were no ocular or systemic complications associated with intravitreal bevacizumab injection. CONCLUSIONS: Early intravitreal bevacizumab injection could be an effective treatment option for patients with vision loss associated with traumatic choroidal rupture and subretinal fluid within the posterior pole before development of CNV.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers
Yonsei Authors
Koh, Hyoung Jun(고형준) ORCID logo https://orcid.org/0000-0002-5932-8516
Kim, Min(김민) ORCID logo https://orcid.org/0000-0003-1873-6959
Seo, Yuri(서유리)
Lee, Sung Chul(이성철) ORCID logo https://orcid.org/0000-0001-9438-2385
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.